ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Drops Pursuit Of AstraZeneca

Two drug majors to go separate ways after failed takeover attempt

by Ann M. Thayer
May 30, 2014 | APPEARED IN VOLUME 92, ISSUE 22

Pfizer ended its attempt to take over AstraZeneca last week after the British firm rejected its final $119 billion offer. “We continue to believe that our final proposal was compelling and represented full value,” Pfizer CEO Ian C. Read said.

In turning down the U.S. company’s bid, AstraZeneca Chairman Leif Johansson declined to heed some shareholders who wanted him to at least engage in talks. Rather, Johansson said he preferred to take “the opportunity to continue building on the momentum we have already demonstrated as an independent company.”

Pfizer is now bound by U.K. takeover code, which prevents it from making an offer for three months, according to ISI Group analyst Mark Schoenebaum, who has been following the saga. Any offer within six months would require consent from AstraZeneca or an exception from the takeover board, Schoenebaum says.

The two big pharma companies now separately face the task of turning around their lackluster financial performance of recent quarters. For its part, AstraZeneca anticipates positive drug development news in the coming months.

Meanwhile, rather than pursuing another megamerger, Pfizer is apt to “focus on bolt-on acquisitions in areas where AstraZeneca would have given them some added strength,” Credit Suisse analyst Vamil Divan said in a recent report. Such areas include immuno-oncology, inflammation, and emerging markets, he added.

Pfizer recently reiterated that its long-term strategy, with or without the AstraZeneca deal, is to split into three parts: innovative pharmaceuticals; generic drugs; and vaccines, oncology, and consumer health.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment